Picrasidine N Is a Subtype-Selective PPARβ/δ Agonist.

@article{Zhao2016PicrasidineNI,
  title={Picrasidine N Is a Subtype-Selective PPAR$\beta$/$\delta$ Agonist.},
  author={Shuai Zhao and Yuichiro Kanno and Wei Li and Honami Wakatabi and Tatsunori Sasaki and Kazuo Koike and Kiyomitsu Nemoto and Huicheng Li},
  journal={Journal of natural products},
  year={2016},
  volume={79 4},
  pages={
          879-85
        }
}
Recently, growing evidence of the pivotal roles of peroxisome proliferator-activated receptor (PPAR) β/δ in various physiological functions, including lipid homeostasis, cancer, and inflammation, has raised interest in this receptor. In this study, the naturally occurring dimeric alkaloid picrasidine N (1) from Picrasma quassioides was identified as a novel PPARβ/δ agonist from a library consisting of plant extracts and natural compounds using a mammalian one-hybrid assay, and this compound was… 
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
TLDR
This is the first report to demonstrate 1 to be a subtype-selective PPARα agonist with potential application in treating metabolic diseases, such as hyperlipidemia, atherosclerosis, and hypercholesterolemia.
Targeting Peroxisome Proliferator-activated Receptor delta (PPARδ): A Medicinal Chemistry Perspective.
TLDR
The challenges of PPARδ selectivity and the medicinal chemistry of most active agonists discovered by different pharmaceutical companies and institutes are focused on.
Nuciferine Inhibits Proinflammatory Cytokines via the PPARs in LPS-Induced RAW264.7 Cells
TLDR
Nuciferine (10 μM) significantly inhibited the lipopolysaccharide (LPS)-induced inflammatory cytokine IL-6 and TNF-α production in RAW 264.7 cells, suggesting a potential molecular mechanism of the anti-inflammatory effects of nuciferines in LPS-induced inflammation.
Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome
TLDR
The three PPARs have complementary roles in the fine-tuning of most fundamental body functions, especially energy metabolism, so understanding their inter-relatedness using ligands that simultaneously modulate the activity of more than one of these receptors is a major goal.
NSAIDs Induce Proline Dehydrogenase/Proline Oxidase-Dependent and Independent Apoptosis in MCF7 Breast Cancer Cells
TLDR
Evidence is provided that the studied NSAIDs induce PRODH/POX-dependent and independent apoptosis in MCF7 breast cancer cells.
A novel plausible mechanism of NSAIDs-induced apoptosis in cancer cells: the implication of proline oxidase and peroxisome proliferator-activated receptor
TLDR
A hypothesis on the mechanism of NSAIDs-induced apoptosis in cancer cells is provided and peroxisome proliferator-activated receptor (PPARs) and PPARs are implicated in PRODH/POX-dependent apoptosis are provided.
Anticancer effects of picrasidine I on oral squamous cell carcinoma
TLDR
Analysis of MAPK signaling pathway revealed that picrasidine I‐mediated proapoptotic activities by downregulating JNK phosphorylation is identified as a potent anticancer agent that can be used as a therapeutic intervention against oral squamous cell carcinoma.
FGFR2 regulation by picrasidine Q inhibits the cell growth and induces apoptosis in esophageal squamous cell carcinoma
TLDR
The results are the first to identify that PQ might be a chemopreventive and chemotherapeutic agent by direct targeting FGFR2 and inhibiting cell proliferation of ESCC cells.
...
1
2
...

References

SHOWING 1-10 OF 33 REFERENCES
PPARbeta/delta ligands as modulators of the inflammatory response.
TLDR
Preclinical data suggest that ligands to the beta/delta isoform have activity in a number of disease models that are partly driven by the inflammatory response, and selective activation of PPARbeta/ delta may represent a promising therapeutic approach for the treatment of diseases that have inflammation as a central component of their pathophysiology.
Peroxisome proliferator-activated receptors: from genes to physiology.
TLDR
Given the fundamental roles that the PPARs play in energy balance, drugs that modulate PPAR activity are likely to be useful for treating a wide range of metabolic disorders, including atherosclerosis, dyslipidemia, obesity, and type 2 diabetes.
Nigramide C Is a Natural Agonist of Human Pregnane X Receptor
TLDR
During a screening of a natural compounds library for novel ligands of human xenosensing receptors by the mammalian one-hybrid assay, NigC was found to be an effective agonist of hPXR.
Nigramide J is a novel potent inverse agonist of the human constitutive androstane receptor
TLDR
Nigramide J (NJ) is a naturally occurring cyclohexane‐type amide alkaloid that was isolated from the roots of Piper nigrum whose efficacy is comparable to those of hitherto known inverse agonists such as clotrimazole, PK11195, and ethinylestradiol.
Meta-analysis of primary target genes of peroxisome proliferator-activated receptors
TLDR
An in silico screening approach is presented, which allows increased sensitivity of PPAR binding site and target gene detection and limited conservation of PPRE patterns, although PPAR target genes typically contain strong or multiple medium strength PPREs.
...
1
2
3
4
...